Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes

Abstract

This large-scale genomic characterization of PMBCL identified novel treatment targets and genetic lesions for refined risk stratification. <i>DUSP2</i> and <i>CD58</i> mutation analyses may guide treatment decisions between rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone and dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab.